EFFICACY AND SAFETY OF PYRONARIDINE TETRAPHOSPHATEARTESUNATE FOR TREATMENT OF UNCOMPLICATED Plasmodium falciparum MALARIA IN BINH PHUOC, GIA LAI AND PHU YEN PROVINCES, VIET NAM, IN 2021
DOI:
https://doi.org/10.59253/tcpcsr.v132i6.189Tóm tắt
From March to December 2021, this prospective, open-label, single-arm
observational clinical trial, conducted in Binh Phuoc, Gia Lai and Phu Yen provinces,
evaluated the safety and efficacy of oral Pyronaridine tetraphosphate-Artesunate oncedaily for three consecutive days in adults and children with microscopically confirmed
P. falciparum malaria. Patients were treated as in-patients for Days 0–3, with followup visits on Days 7, 14, 21, 28, 35 and 42. The primary outcome was PCR-adjusted
adequate clinical and parasitological response (ACPR) at Day 42. The results from 54
P. falciparum patients has shown that: The efficacy of Pyronaridine tetraphosphate -
Artesunate to P. falciparum has still high, with the rate of ACPR is 100%, the rate of
positive parasitemia at day 3 is 50%, 54.5% and 54.8% in Binh Phuoc, Phu Yen and
Gia Lai, respectively. Pyronaridine-Artesunate is safety for the patients. None serious
adverd event are recorded.